肝硬化门静脉血栓形成的相关危险因素

doi:10.6040/j.issn.1671-7554.0.2018.183

摘要/Abstract

摘要： 目的探讨肝硬化患者门静脉血栓(PVT)形成的相关危险因素。方法回顾性分析1 670例肝硬化患者病例资料,将其中217例发生PVT者纳入PVT组,随机选择250例未发生PVT者纳入非PVT组。记录两组患者的一般资料、实验室检查结果、临床表现及并发症、手术及药物应用史情况,运用单因素分析和多因素分析方法寻找肝硬化PVT发生的相关危险因素。结果 1 670例肝硬化患者中13%并发PVT,肝功能分级以Child-Pugh B和C级为主。单因素分析显示,两组在D-二聚体、Hb、TBiL、重度食管静脉曲张、脾切除手术、止血药物及心得安使用方面差异均有统计学意义(P<0.05)。多因素非条件Logistic回归分析显示,重度食管静脉曲张(OR=6.918, P=0.018)、脾切除手术(OR=4.281, P=0.007)、D-二聚体升高(OR=5.007, P<0.001)为肝硬化PVT形成的独立危险因素。结论止血药物、心得安、D-二聚体升高、重度食管静脉曲张、脾切除术均可能与肝硬化PVT的形成有关,其中重度食管静脉曲张、脾切除术、D-二聚体升高为肝硬化PVT形成的独立危险因素。

关键词: 肝硬化, 静脉血栓形成, 门静脉, 危险因素

Abstract: Objective To investigate the risk factors of portal vein thrombosis(PVT)in cirrhotic patients. Methods The clinical data of 1 670 hospitalized cirrhotic patients were retrospectively analyzed, of whom 217 with PVT were classified into the PVT group, while 250 without PVT were randomized into the non-PVT group. The general information, laboratory results, clinical manifestations, complications, surgery and drug administration history of the two groups were recorded. The risk factors of PTV were analyzed with univariate analysis and multivariate Logistic regression analysis. Results Of the 1 670 cirrhotic patients, 13% developed PVT, whose liver function was classified as Child-Pugh B and C. Univariate analysis showed significant differences in d-dimer, hemoglobin(Hb), total bilirubin(TBiL), severe esophageal varices, previous splenectomy, hemostatic drugs and propranolol between the two groups. Multivariate Logistic regression analysis showed that severe esophageal varices(OR=6.918, P=0.018), previous splenectomy(OR=4.281, P=0.007)and increase of d-dimer(OR=5.007, P<0.001)were independent risk factors of PVT. Conclusion Hemostatic drugs, propranolol, increase of d-dimer, severe esophageal varices, previous splenectomy may be associated with the formation of PVT in cirrhotic patients. Severe esophageal varices, previous splenectomy and increase of d-dimer are independent risk factors of PVT.

Key words: Liver cirrhosis, Venous thrombosis, Portal vein, Risk factors

中图分类号:

R575.2

丁艳菲,杨卓鑫,郑文文,袁文杰,高艳景. 肝硬化门静脉血栓形成的相关危险因素[J]. 山东大学学报 (医学版), 2018, 56(12): 13-18.

DING Yanfei, YANG Zhuoxin, ZHENG Wenwen, YUAN Wenjie, GAO Yanjing. Risk factors of portal vein thrombosis in patients with liver cirrhosis[J]. Journal of Shandong University (Health Sciences), 2018, 56(12): 13-18.

参考文献

[1] Shah SL, Anderson JC, Shatzel JJ, et al. The epidemiology and clinical associations of portal vein thrombosis in hospitalized patients with cirrhosis: a nationwide analysis from the national inpatient sample[J]. J Hosp Med, 2018, 13(5):324-325.
[2] Qi X, Han G, Fan D. Management of portal vein thrombosis in liver cirrhosis[J]. Nat Rev Gastroenterol Hepatol, 2014, 11(7): 435-446.
[3] 臧立娜, 孙自勤, 刘文波, 等. 食管胃静脉曲张经内镜治疗后再出血危险因素的Meta分析[J]. 中华肝脏病杂志, 2015, 23(4): 275-280. ZANG Lina, SUN Ziqin, LIU Wenbo, et al. Meta-analysis of risk factors of gastroesophageal varices rebleeding after therapeutic endoscopy[J]. Chinese Journal of Hepatology, 2015, 23(4): 275-280.
[4] Dell'era A, Iannuzzi F, Fabris FM, et al. Impact of portal vein thrombosis on the efficacy of endoscopic variceal band ligation[J]. Dig Liver Dis, 2014, 46(2): 152-156.
[5] Qi X, Dai J, Yang M, et al. Association between portal vein thrombosis and survival in non-liver-transplant patients with liver cirrhosis: a systematic review of the literature[J]. Gastroenterol Res Pract, 2015, 2015: 480842. doi:10.1155/2015/480842.
[6] Bagheri Lankarani K, Homayon K, Motevalli D, et al. Risk factors for portal vein thrombosis in patients with cirrhosis awaiting liver transplantation in shiraz, iran[J]. Hepat Mon, 2015, 15(12): e26407. doi:10.5812/hepatmon.26407.
[7] Ghabril M, Agarwal S, Lacerda M, et al. Portal vein thrombosis is a risk factor for poor early outcomes after liver transplantation: analysis of risk factors and outcomes for portal vein thrombosis in waitlisted patients[J]. Transplantation, 2016, 100(1): 126-133.
[8] Nery F, Chevret S, Condat B, et al. Causes and consequences of portal vein thrombosis in 1,243 patients with cirrhosis: results of a longitudinal study[J]. Hepatology, 2015, 61(2): 660-667.
[9] Kinjo N, Kawanaka H, Akahoshi T, et al. Portal vein thrombosis in liver cirrhosis[J]. World J Hepatol, 2014, 6(2): 64-71.
[10] Abdel-Razik A, Mousa N, Elhelaly R, et al. De-novo portal vein thrombosis in liver cirrhosis: risk factors and correlation with the Model for End-stage Liver Disease scoring system[J]. Eur J Gastroenterol Hepatol, 2015, 27(5): 585-592.
[11] Harding DJ, Perera MT, Chen F, et al. Portal vein thrombosis in cirrhosis: Controversies and latest developments[J]. World J Gastroenterol, 2015, 21(22): 6769-6784.
[12] Francoz C, Valla D, Durand F. Portal vein thrombosis, cirrhosis, and liver transplantation[J]. J Hepatol, 2012, 57(1): 203-212.
[13] Maruyama H, Okugawa H, Takahashi M, et al. De novo portal vein thrombosis in virus-related cirrhosis: predictive factors and long-term outcomes[J]. Am J Gastroenterol, 2013, 108(4): 568-574.
[14] Violi F, Corazza GR, Caldwell SH, et al. Portal vein thrombosis relevance on liver cirrhosis: Italian Venous Thrombotic Events Registry[J]. Intern Emerg Med, 2016, 11(8): 1059-1066.
[15] Francoz C, Belghiti J, Vilgrain V, et al. Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation[J]. Gut, 2005, 54(5): 691-697.
[16] Morisaka H, Motosugi U, Ichikawa T, et al. MR-based measurements of portal vein flow and liver stiffness for predicting gastroesophageal varices[J]. Magn Reson Med Sci, 2013,12(2): 77-86.
[17] Tarzamni MK, Somi MH, Farhang S, et al. Portal hemodynamics as predictors of high risk esophageal varices in cirrhotic patients[J]. World J Gastroenterol, 2008, 14(12): 1898-1902.
[18] Zocco MA, Di Stasio E, De Cristofaro R, et al. Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development[J]. J Hepatol, 2009, 51(4): 682-689.
[19] Ikeda M, Sekimoto M, Takiguchi S, et al. High incidence of thrombosis of the portal venous system after laparoscopic splenectomy: a prospective study with contrast-enhanced CT scan[J]. Ann Surg, 2005, 241(2): 208-216.
[20] Li MX, Zhang XF, Liu ZW, et al. Risk factors and clinical characteristics of portal vein thrombosis after splenectomy in patients with liver cirrhosis[J]. Hepatobiliary Pancreat Dis Int, 2013, 12(5): 512-519.
[21] Matsumoto T, Yamagami T, Terayama K, et al. Risk factors and clinical course of portal and/or splenic vein thrombosis after partial splenic embolization[J]. Acta Radiol, 2009, 50(6): 617-623.
[22] 李征然, 单鸿, 朱康顺, 等. 部分性脾栓塞术改变门脉血流动力学的定量研究[J]. 中华放射学杂志, 2002, 36(10): 913-917. LI Zhengran, SHAN Hong, ZHU Kangshun, et al. Clinical quantitative study of therapeutic effect of partial splenic embolization(PSE)on portal vein hemodynamics[J]. Chinese Journal of Radiology, 2002, 36(10): 913-917.
[23] Pellicelli AM, Ambrosio CD, Barbaro G, et al. Clinical and genetic factors associated to development of portal vein thrombosis in cirrhotic patients without hepatocellular carcinoma[J]. Journal of Hepatology, 2011, 54: S77. doi:10.1016/S0168-8278(11)60182-7.
[24] Zampino R, Lebano R, Coppola N, et al. The use of nonselective beta blockers is a risk factor for portal vein thrombosis in cirrhotic patients[J]. Saudi J Gastroenterol, 2018, 24(1): 25-29.
[25] Qi XS, Bai M, Fan DM. Nonselective β-blockers may induce development of portal vein thrombosis in cirrhosis[J]. World J Gastroenterol, 2014, 20(32): 11463-11466.
[26] Dai J, Qi X, Li H, et al. Role of D-dimer in the development of portal vein thrombosis in liver cirrhosis: a meta-analysis[J]. Saudi J Gastroenterol, 2015, 21(3): 165-174.
[27] de Franchis R, Baveno VI Faculty. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension[J]. J Hepatol, 2015, 63(3): 743-752.
[28] 中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会内镜学分会, 等. 肝硬化门静脉高压食管胃静脉曲张出血防治指南(2015)[J]. 中华胃肠内镜电子杂志, 2015, 2(4): 1-21.

相关文章 15

[1]	王韶卿刘毅慧付婷婷成金勇刘强. 肝癌³¹磷磁共振波谱数据的分类[J]. 山东大学学报(医学版), 2209, 47(6): 42-46.
[2]	黄玉真,吕琛,颜磊,李帅帅,张景雪,刘超,王银霞,桑岩岩,房鹛. 基于危险因素筛查的延续性院外管理对卵巢过度刺激综合征的预防效果[J]. 山东大学学报 (医学版), 2026, 64(4): 92-99.
[3]	逄锦宏,苏萍,乔俊鹏,陈巧巧,陈学禹,赵颖颖,施婕,孙晓茹,李秋春,何蕊言,范轶欧,迟蔚蔚. 老年人群可改变心血管危险因素聚集模式与脑卒中的关联[J]. 山东大学学报 (医学版), 2025, 63(9): 11-19.
[4]	张政,王建伟,杨玉娟,张宇,宋西成. 哮喘儿童2008及2019年免疫球蛋白E变化及相关危险因素[J]. 山东大学学报 (医学版), 2025, 63(7): 32-36.
[5]	李敬,郝盼盼. 急性心力衰竭患者出入院心率变化与预后相关性[J]. 山东大学学报 (医学版), 2025, 63(4): 75-82.
[6]	程震宇,来庆国,吴梦涛. 髂股静脉支架置入术后再狭窄的影响因素研究进展[J]. 山东大学学报 (医学版), 2025, 63(12): 112-117.
[7]	程跃启,王斐,于理想,郑超,余之刚. 曲妥珠单抗致HER2阳性乳腺癌患者心脏毒性的研究进展[J]. 山东大学学报 (医学版), 2025, 63(1): 17-24.
[8]	王浙宇,许懿,赵昌波,杨硕菲,倪其泓,陈佳佺,王韦仑,李一男,郭相江,叶猛,张岚,薛冠华. 腹主动脉瘤腔内修复术后发生髂支闭塞的危险因素及处理对策[J]. 山东大学学报 (医学版), 2024, 62(9): 101-107.
[9]	郭鑫,孟君,郑世良,董秀红. 老年胃癌患者衰弱与人体成分的相关性[J]. 山东大学学报 (医学版), 2024, 62(4): 40-47.
[10]	李建,孙云. 新入维持性血液透析患者2年内死亡的危险因素[J]. 山东大学学报 (医学版), 2024, 62(4): 48-53.
[11]	宋甜田,李作坤,王书会. 个体化预测老年心脏瓣膜置换术后医院感染风险Nomogram模型的构建[J]. 山东大学学报 (医学版), 2024, 62(1): 48-56.
[12]	朱金羽,高帅,王凯. 控制营养状态评分在乙肝肝硬化中的临床价值[J]. 山东大学学报 (医学版), 2023, 61(7): 72-77.
[13]	曲永强,赵泽宇,吴兴原,韩玮,段瑞生,李衍滨,李亨. 颈动脉分叉处支架置入术后严重持续性低血压的危险因素[J]. 山东大学学报 (医学版), 2023, 61(7): 78-82.
[14]	宋晗,王振华,韦铎亮,徐凯,李博文,赵鑫. 术前MELD分级对304例急性StandfordA型主动脉夹层患者术后早期结局的影响[J]. 山东大学学报 (医学版), 2023, 61(5): 31-36.
[15]	张蒙,马伟. 1990—2019年中国人类免疫缺陷病毒/获得性免疫缺陷综合征流行趋势及疾病负担[J]. 山东大学学报 (医学版), 2023, 61(5): 84-89.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed